GRI Bio (GRI) Notes Payables (2020 - 2022)
GRI Bio (GRI) posted quarterly Notes Payables of $602000.0 for Q4 2022, up 1180.85% quarter-over-quarter from $47000.0 in Q4 2020.
GRI Bio (GRI) Notes Payables (2020 - 2022) Analysis & Trends
GRI Bio's Notes Payables history runs 2 years deep, the most recent figure standing at $602000.0 for Q4 2022.
- In Q4 2022, Notes Payables changed N/A year-over-year to $602000.0; the TTM figure through Dec 2022 stood at $602000.0 (changed N/A YoY), while the FY2022 annual figure was $602000.0, changed N/A from the prior year.
- Notes Payables for Q4 2022 stood at $602000.0, up from $47000.0 in the prior quarter.
- The five-year high for Notes Payables was $602000.0 in Q4 2022, with the low at $47000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | GRI Bio | 3.03 Mn | 3.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 602,000.00 |
| Dec 31, 2020 | 47,000.00 |